The European health regulator has vowed to conduct a speedy review of Gilead Sciences’ potential COVID-19 drug, remdesivir, but said it has not yet received an application from the US drugmaker.
The European Medicines Agency (EMA) said on Friday its human medicines committee’s (CHMP) timeline to assess the drug would be “reduced to the absolute minimum,”.
The announcement comes two weeks after the EMA head told the European Parliament it may give an initial green light for sale of remdesivir as a COVID-19 treatment, fast-tracking the drug to market amid tight global competition for resources.
There are currently no approved medication or vaccine for the highly-contagious and sometimes fatal illness.
The United States, the world’s biggest pharmaceutical market, earlier this month granted emergency use authorization for remdesivir in COVID-19, clearing the way for broader use of the drug, but is yet to approve it.
The EMA has been reviewing the drug periodically and suggested a beneficial effect in treating hospitalised patients with mild-to-moderate or severe COVID-19.
While final approvals are up to the European Commission, it generally takes and endorses CHMP recommendations.
More Stories
Survivors Ever Fewer In Earthquake Rubble Of Turkey And Syria
EU Invites Ukraine’s Zelenskyy To Brussels Summit
Powerful Earthquake Kills More Than 5,000 In Turkey, Syria
China Balloon Over U.S. Deflates Hopes For Diplomatic Thaw
Zelenskyy Meets with European Leaders
African Nations Commit To Ending AIDS In Children By 2030
FBI Searches Biden Home, Finds Documents Marked Classified
Troubleshooter Chris Hipkins Faces A Tough Road As New Zealand PM
UN Says 49 Bodies Found In Congo Mass Graves
US Announces More Than $3B In Military Aid To Ukraine
Kevin McCarthy Elected Republican U.S. House Speaker, But At A Cost
Britain Says Russia May Have Stored Ammunition At Site Of Barracks Attack